Michael Huang

Michael Huang currently serves as Managing Partner of Taiwania Capital’s life science fund. Prior to joining Taiwania, Michael was the co-founder and CEO of NeuroVive Pharmaceutical Asia, Inc. (NVP Asia), a new drug development company focusing on the development of mitochondria-related diseases. During his tenure, NVP Asia had successfully signed out-licensing deals with global and Chinese pharmas. Michael has over 20 years of experience in investing and managing early to late-stage biotech and medical device companies in Greater China, Japan, European and North America regions. Michael received his MS degree in chemistry from University of Texas at Arlington and an MBA degree from Rice University.